Healthcare >> Analyst Interviews >> March 11, 2016
Stronger Growth Expected for Life Science Tools and Diagnostics
Bryan Brokmeier, CFA, is a Senior Equity Research Analyst in life science tools and diagnostics at Cantor Fitzgerald. Prior to joining Cantor Fitzgerald, Mr. Brokmeier was a Senior Health Care Analyst at Maxim Group, where he covered the life science tools and diagnostics sector. In 2014, Mr. Brokmeier was ranked the number three stock picker in the life science tools and services category by Thomson Reuters StarMine. Before that, Mr. Brokmeier held senior research associate positions within Maxim Group and Credit Suisse Group. Mr. Brokmeier received an MBA from Kelly School of Business at Indiana University and a B.S. in finance and applied economics from Ithaca College, and is a CFA charterholder. Profile
TWST: What is your coverage?
Mr. Brokmeier: I cover life science tools and diagnostics companies such as Affymetrix (NASDAQ:AFFX),